All In MedTech

Device Trial Radar · NCT05543798

VT Ablation in the iCMR

Vision-MR Ablation Catheter 2.0 for the Treatment of Ventricular Tachycardia

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Apr 10, 2025

Primary completion

Jul 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Imricor Medical SystemsNot on our public-company list
Sponsor type
Industry
First posted
Sep 16, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The VISABL-VT is a prospective, single-arm, multi-center, interventional investigation of the safety and efficacy of radiofrequency (RF) ablation of ventricular tachycardia associated with ischemic cardiomyopathy performed with the Vision-MR Ablation Catheter 2.0 in the iCMR environment.

Conditions

  • Ventricular Tachycardia

Interventions

  • Vision-MR Ablation Catheter 2.0Device

    Catheter ablation of ventricular tachycardia

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary Efficacy EndpointTime frame: Perioperative/Periprocedural
  2. Primary Safety EndpointTime frame: 7 days

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Herzzentrum Leipzig

    Leipzig, Saxony, Germany · Not yet recruiting

  • Amsterdam UMC

    Amsterdam, Netherlands · Recruiting

  • HagaZiekenhuis

    The Hague, Netherlands · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.